http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2603935-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d1596f64ec0b2dac5334b2cf05b88bb |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 |
| filingDate | 2006-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bcab26da6b5c712594a99a0f018b4c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9cecb31e518a76c3931b25440d5677b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_607469171112395c8d37b9e486c5f023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a48908e8eef4a31b835bd35f710ea45 |
| publicationDate | 2006-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2603935-A1 |
| titleOfInvention | Uses of 2-phenyl-substituted imidazotriazinone derivatives for treating pulmonary hypertension |
| abstract | The invention relates to the use of PDE 5 inhibitors in general and especially of known 2-phenyl-substituted imidazotriazinone derivatives, such as e.g. Vardenafil, for producing drugs used in the treatment of clinical pictures that can be treated by increasing the cGMP levels in certain tissues, for example of diseases such as primary pulmonary hypertension, secondary pulmonary hypertension, pulmonary arterial hypertension, portopulmonary hypertension, hepatopulmonary syndrome, pulmonary hypertension caused by drugs (amphetamines), interstitial lung disease, HIV-related pulmonary hypertension, thromboembolic pulmonary hypertension, pulmonary hypertension in children and newborn children, atmospheric hypoxia-induced pulmonary hypertension (mountain sickness), COPD, emphysema, chronic bronchial asthma, cystic fibrosis-related pulmonary hypertension, right ventricular failure, left ventricular failure and global failure, and that can be treated by increasing the cGMP levels in certain tissues, such as for example isolated systolic hypertension (ISH) and vascular sclerosis, in particular arterial blood vessels. The invention also relates to the combinations of PDE 5 inhibitors in general and especially of known 2-phenyl-substituted imidazotriazinone derivatives with additional therapeutic agents for the indications mentioned above. |
| priorityDate | 2005-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 502.